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TCT-511
Percutaneous Transluminal Angioplasty of the Subclavian Arteries. Long-Term
Follow up.
Isabelle P. henry1, Amira Benjelloun2, Michel C. henry3
1Polyclinique Bois Bernard, Bois Bernard, France, 2Clinique Coeur et Vaisseaux,
Rabat, Morocco, 3Cabinet de cardiologie, Nancy, France
Background: To review feasibility, safety and long-term results of subclavian artery
angioplasty.
Methods: 407 patients (males: 245, mean age: 66.1  12 y) underwent percutaneous
treatment for subclavian artery (SA) occlusive disease (stenosis: 295, occlusion: 112).
Left: 312, Right: 95, Innominate Artery: 28. Etiology: atheromatous: 397, others: 10
(Takayasu: 6) Mean % stenosis 83.4 +/- 7.8. Mean lesion length: 23.9 +/- 8.7 mm
Indications for treatment were upper limb ischemia (ULI) (n¼177) Vertebrobasilar
insufﬁciency (VBI) (n¼157), associated VBI and ULI (n¼123), coronary steal
syndrome (n¼20) asymptomatic patients with severe coronary disease (n¼73) 39
patients had associated Vertebral Artery stenosis, 81 carotid stenoses. 337 prevertebral
lesion, 45 post vertebral, both 25. Access: femoral (n¼287), brachial (n¼81), both
(n¼39). "Pull through technique": 8 cases. An isolated balloon angioplasty was per-
formed in 59 cases and 348 stents were implanted (balloon expandable: 276, self
expandable: 72).
Results: Technical success was obtained in 387 lesions (95 %) 100% for stenoses.
Only 92 occlusions were recanalized (82 %). Four periprocedural events occurred
(1.2 %), 1 major (fatal stroke), 1 T.I.A., 2 arterial thromboses. During the follow-up
(mean follow-up: 75.7 months  38.5), we had 40 restenoses (10 %). 13 occurred
following angioplasty alone (18.8 %) and 27 following angioplasty and stent
implantation (7.8 %) (P<0.01). 10 were treated by new angioplasty alone, 30 by
repeat stent implantation. Primary (PI) and secondary (PII) patencies on an intention to
treat basis at 10-year follow-up were 80.2 % and 86.5 % respectively. In patients
without initial stent placement, the rates were 67.5 % and 75.5 % while in those with
stents, the rates rose to 91.5 % and 98.2 % (P < 0.01). PI for all recanalized lesions
were 85.8 %, 79.1 % without stent, 91.8 % with stent (P < 0.04) and PII 92.8 %,
88.5 %, 98.1% respectively (P < 0.02).
Conclusions: P.T.A. is currently the treatment of choice for subclavian artery
lesions. It is a safe and effective procedure associated with low risks and good
long-term results. Stents seem to limit the restenosis rate and improve long-term
results.
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Background: Despite good immediate and long-term results, post procedural dete-
rioration of the renal function (RF) may occur after Renal Artery Angioplasty and
Stenting (RAAS) in 20-40 % of the patients, which limits the immediate beneﬁts of
the technique. Atheroembolism seems to play an important role. We evaluate feasi-
bility and safety of RAAS utilizing a distal protection device (DPD) to reduce the risk
of atheroembolism and avoid deteriorations of the RF.
Methods: 171 RAAS performed under DPD in 151 hypertensive patients (M:102).
Mean age: 65.2  10.8 yrs with atherosclerotic renal artery stenosis (20 bilateral). 11
pts had solitary kidneys, 62 renal insufﬁciencies. We used occlusion balloon (n ¼ 46)
or ﬁlters (n ¼ 125). We recently experimented and treated 12 patients with a new ﬁlter
the Fibernet (Lumen Biomedical Plymouth MN) which can capture particles of 40m
without compromising the ﬂow. Generated debris removed and analyzed. Blood
pressure and serum creatinine levels followed. Techniques of RAAS under protection,
limitations will be discussed.
Results: Immediate technical success: 100 %. Visible debris aspirated with Percu-
surge from all patients. Mean particle number: 98.1  60.00. Mean diameter: 201.2 
76m (38-6206). With current ﬁlters debris were removed in 80 % of the cases. With the
Fibernet visible debris were removed in all cases. Mean debris surface area: 121mm2.
Mean number of particles 28-60m : 2136  776, >60m. We observed one acute RF
deterioration. Mean follow-up: 32.2  17 months. Mean creatinine level remains
constant during follow-up. At 6 months (131 patients) 95 patients stabilized, 35 with
baseline renal insufﬁciency improved and we had only one RF deterioration (1 %) inB156 JACC Vol 62/18/Suppl B j October 27–Na patient with moderate renal insufﬁciency. At 2 years (105 patients) 73 stabilized, 28
improved and we only had 4 RF deterioration (4 %).
Conclusions: This study demonstrates the feasibility and safety of DPD during
renal interventions to protect against atheroembolism and seems to avoid RF deteri-
oration after the procedure and in the long-term. Indications will be discussed.
Improvements in DPD for renal stenting are mandatory. Randomized studies are
awaited.
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Background: Renal Artery Aneurysms (RAAs) can be surgically treated but due to
high risk, endovascular procedures have been proposed (coils, graft.). All
these techniques have some drawbacks, potential complications and contraindications.
We propose a new technique: the Multilayer Flow Modulator (MFM*), a self
expandable.
Methods: This MFM* is a 3D braided tube made of several interconnected
layers without any covering. Our earliest tests, in vitro (theoretical simulation
computerized Fluid dynamics, Molecular Modelization) & in vivo. demonstrate
that this MFM* reduces the velocity in the aneurismal sac up to 90% by modifying
the hemodynamic conditions.. A saccular aneurysm (A.) without collateral branch
will thrombose quickly. If a collateral branch is present the ﬂow is directed
towards this branch leading to shrinkage of the aneurysm. In fusiform A. the
ﬂow is laminated, the vortexes eliminated, eliminating the risk of rupture.
Animal experiments show excellent results. Moreover, as demonstrated in animal
and human studies this MFM preserves the collateral branches and increases the
ﬂow in them, allowing the possibility to cover any artery without compromising
the ﬂow.
Results: 8 RAAs (right:5, left: 3) in 8 pts (male: 3) mean age 58 y. treated with MFM*
6 pts had atheromatous disease, 2 a ﬁbromuscular dysplasia. One pt had a solitary
kidney. All these pts had hypertension. 10 MFM*(Ø: 5 to 6 mm, length 30 to 60 mm)
loaded in a 6 F sheath implanted by femoral approach through 8 F guiding catheter.
These stents covered major renal branches without compromising the ﬂow. Technical
success: 100%. No complications. Immediately: important reduction of the velocities
inside the aneurismal sac. 6 to 36 month follow up will be presented. All aneurysms
thrombosed with diameter reduction in some pts. The thrombosis could take several
weeks depending on the importance of collateral branches. All the side branches
remain patent.
Conclusions: The MFM* is a new technique which seems promising to treat RAAs.
Collateral branches can be covered without compromising the ﬂow and risk of renal
infarction. It is a safe procedure with a very low complications rate. Larger study is
ongoing.
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Background: Popliteal Artery Aneurysms (PA) are traditionally treated surgically.
Endovascular procedures with implantation of stent grafts or covered stents have been
proposed as an alternative to surgery. Results are encouraging but some problems
remain (aneurysm rupture, endoleaks, collateral branch thrombosis.). We used a new
concept of stent, the Multilayer Flow Modulator (MFM*) to treat aneurysms and try to
avoid some drawbacks encountered with endografts.
Methods: This MFM* is a 3 Dimensional braided tube made of several inter-
connected layers without any covering. Our earliest tests in vitro (theorical
simulation, computerized Fluid dynamics, Molecular Modelization) and in vivo
demonstrate that this MFM* reduces the velocity in the aneurismal sac up to 90% by
modifying the hemodynamic conditions. A saccular aneurysm without collateral
branch will thrombose quickly. If a collateral branch is present the ﬂow is direc-
ted towards this branch leading to shrinkage of the aneurysm. Animal ex-
periments show excellent results. Moreover, as demonstrated in animal and human
studies this MFM* preserves the collateral branches allowing the possibility to cover
any artery without compromising the ﬂow (renal, digestive arteries, supra aortic
vessels .).
Results: 5 PA were treated with the MFM* (male: 5, mean age: 65 y.) 9 stents (Ø6 to
8 mm, length 40 to 120 mm) were implanted by percutaneous ipsilateral femoral
approach through 8F sheath. Technical success in all patients. All aneurysm throm-
bosed. Mid-term follow up will be presented. No stent fracture. This MFM* seems
well indicated for this popliteal location.
Conclusions: A new concept of stent, the MFM* is developed to treat aneurysm. It
opens a new approach to treat peripheral aneurysms avoiding most of theovember 1, 2013 j TCT Abstracts/POSTER/Endovascular Intervention
